期刊文献+

2008年--2010年我门诊部口服抗高血压药应用分析 被引量:1

Analysis of the Application of Anti-hypertensive Drugs in Our Hospital During the Period of 2008-2010
在线阅读 下载PDF
导出
摘要 目的:调查我部门诊抗高血压药物应用情况,为临床合理用药提供参考依据。方法:采用限制日剂量方法.统计分析我部门诊2008~2010年用药频度(DDDs),并对各种高血压药物金额、高血压药物种类金额及所占比例进行回顾性统计分析。结果:用药频度及金额排序靠前的有硝苯地平《包括缓释、控释》、苯磺酸氨氯地平(包括左旋).非洛地平缓释用量逐年增大;钙通道阻滞剂是临床使用最多的降压药物.单品种排序,苯磺酸左旋氨氯地平各年均居首位,非洛地平缓释片上升较高.2010年达第二位。结论:我门诊部高血压药物使用较平稳.应用基本符合当前高血压治疗原则。 Objective: To investigate the utilization status of anti-hypertensive drugs in our hospital and provide references for the rational application in the clinic. Methods: The anti-hypertensive drugs used in Outpatient Dispensary of our hospitals in 2008-2010 were statistically analyzed in respect of DDDs, drug consumption sum, the varieties and their proportions. Results: Extended-release and controlled-release Nifedipine tablets, Amlodipine Besylate tablets, Felodipine sustained-release tablets with drug consumption increased year by year occupied the first three places in consumption sum and DDDs. CCB was the most popular type of anti-hypertensive drugs. In the category of CCB, Levo Amlodipine ranked the first place of DDDs every year; the utilization of Felodipine sustained-release tablets was increased during these years, and ranked second in 2010. Conclusion: The application of anti-hypertensive drugs was steady. It was consistent with the standard recommended by the guideline for prevention and treatment of hypertension in China.
作者 张新萍
出处 《药品评价》 CAS 2011年第24期36-38,共3页 Drug Evaluation
关键词 口服抗高血压药物 药物分析 销售金额 用药频度 Oral anti-hypertensive drugs Analysis of drug use Consumption sum DDDs
作者简介 张新萍,女,主管药师,主要从事药事管理学研究。电话:66816254;E-mail:zxpyy@chiaren.com
  • 相关文献

参考文献5

二级参考文献21

  • 1管弦,余江毅.糖尿病高血压的治疗[J].临床内科杂志,2004,21(10):717-719. 被引量:22
  • 2孙宁玲.血管紧张素受体拮抗剂在高血压治疗中的作用及地位[J].中华医学杂志,2005,85(25):1732-1733. 被引量:34
  • 3谌贻璞.ACEI与ARB肾脏保护作用研究进展[J].中国医药导刊,2007,9(2):122-124. 被引量:28
  • 4中国高血压防治指南修订委员会.中国高血压防治指南(2005年修版)[J].高血压杂志,2005,134(z):2-41.
  • 5Bryan Williams. Recent hypertension Trials implications and controversies [J]. J ACC,2005,45(6) :813 -827.
  • 6Messerli FH, Grossman E. Pedal edema - not all dihydropyridine calcium antagonists are created equal. Am J Hypertens, 2002, 15 ( 11 ) : 1019 - 1020.
  • 7海日古丽.卡德尔,陈晓霞,依力哈木.高血压患者用药处方分析[J].中国现代医生,2007,45(09X):87-87. 被引量:13
  • 8Julius S,Kjeldsen SE,Weber M,et al.Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trialThe Lancet,2004.
  • 9Lewis EJ;Hunsicker LG;Clarke WR.Collaborative Study Group Renoprotective effect of the angiotension receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes,2001(12).
  • 10Brenner BM;Cooper ME;de Zeeuw D.RENAAL Study lnvestigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy,2001(12).

共引文献22

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部